Advancing Regenerative Medicine Through Innovation
Brinter AM is excited to be a key partner in the KeratoPrinter project—an initiative set to revolutionize corneal tissue engineering by integrating advanced LABP technology. This pioneering approach is designed to overcome critical challenges in treating corneal disorders and restoring vision
Pioneering Innovation in Corneal Bioprinting with KeratOPrinter
KeratOPrinter is at the forefront of technological innovation, setting a new benchmark in regenerative medicine by accelerating the development and validation of a 4D bioprinting suite capable of producing full-thickness corneal grafts. This platform is designed to produce and deliver corneal tissue directly to the clinics, marking a groundbreaking achievement in bioprinting complex tissue structures.
Breakthrough Innovations:
Hypoimmune iPSC-Derived Corneal Cells: Establishing and validating three novel cell types (iCE, iCS, and iCEn) that enhance graft acceptance and reduce immune rejection.
Advanced Clinical-Grade Bioinks: Developing cell-specific bioinks engineered for optimal integration with host tissues, improving graft stability and reducing failure rates.
Novel Corneal Holder Technology: Utilising Melt Electrowriting (MEW) printing to create an innovative corneal holder that supports cell-laden bioprinted corneal grafts and enables secure suturing.
Innovative packaging and logistics solutions: Developing packaging and shipment solutions, essential for preserving the structural integrity of the bioprinted corneal grafts, thereby ensuring their successful implantation.
These pioneering components will be integrated into a state-of-the-art 3D bioprinter with a Laser-Assisted Bioprinting (LaBP) unit capable of producing full-thickness corneal grafts in under two hours. The resulting grafts will replicate the native human cornea’s mechanical and optical properties, ensuring high-performance outcomes.
Brinter AM’s Commitment to Accessible Healthcare
At Brinter AM, we believe that innovation in bioprinting can reshape healthcare by providing scalable, cost-effective, and personalised solutions. Being part of the KeratOPrinter consortium aligns with our mission to make advanced medical technologies accessible to patients worldwide.
We are committed to:
- Leveraging our patented technologies in multi-material and microfluidic printing.
- Supporting research that accelerates the delivery of bioprinted tissue solutions to clinical use.
- Collaborating with leading institutions to ensure quality, reproducibility, and accessibility.
A Strong Partnership for Global Innovation
The STRONG-UR project is powered by a consortium of 9 partners from Five European countries, bringing together expertise from:
- Academic research
- Hospitals
- Industry leaders
This dynamic collaboration combines expertise in cell biology, biomaterials, 3D printing, and eye research , setting new benchmarks in regenerative medicine.
Join Our Mission
We invite you to follow Brinter AM and the KeratOPrinter project as we work towards revolutionizing healthcare through cutting-edge bioprinting solutions.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.
